Last reviewed · How we verify

Bexarotene (Targretin LGD1069)

Beersheva Mental Health Center · Phase 3 active Small molecule

Bexarotene (Targretin LGD1069) is a Retinoid X receptor (RXR) agonist Small molecule drug developed by Beersheva Mental Health Center. It is currently in Phase 3 development for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous manifestations of cutaneous T-cell lymphoma.

Bexarotene is a retinoid X receptor (RXR) agonist that selectively activates RXR to promote differentiation and apoptosis of malignant T cells.

Bexarotene is a retinoid X receptor (RXR) agonist that selectively activates RXR to promote differentiation and apoptosis of malignant T cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous manifestations of cutaneous T-cell lymphoma.

At a glance

Generic nameBexarotene (Targretin LGD1069)
SponsorBeersheva Mental Health Center
Drug classRetinoid X receptor (RXR) agonist
TargetRXR (Retinoid X Receptor)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Bexarotene binds to and activates retinoid X receptors, which are nuclear receptors involved in gene transcription. This activation induces cell cycle arrest and apoptosis in cutaneous T-cell lymphoma cells while also modulating immune responses. The drug's selective RXR agonism distinguishes it from pan-retinoid agonists and allows targeted effects on malignant lymphocytes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bexarotene (Targretin LGD1069)

What is Bexarotene (Targretin LGD1069)?

Bexarotene (Targretin LGD1069) is a Retinoid X receptor (RXR) agonist drug developed by Beersheva Mental Health Center, indicated for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous manifestations of cutaneous T-cell lymphoma.

How does Bexarotene (Targretin LGD1069) work?

Bexarotene is a retinoid X receptor (RXR) agonist that selectively activates RXR to promote differentiation and apoptosis of malignant T cells.

What is Bexarotene (Targretin LGD1069) used for?

Bexarotene (Targretin LGD1069) is indicated for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous manifestations of cutaneous T-cell lymphoma.

Who makes Bexarotene (Targretin LGD1069)?

Bexarotene (Targretin LGD1069) is developed by Beersheva Mental Health Center (see full Beersheva Mental Health Center pipeline at /company/beersheva-mental-health-center).

What drug class is Bexarotene (Targretin LGD1069) in?

Bexarotene (Targretin LGD1069) belongs to the Retinoid X receptor (RXR) agonist class. See all Retinoid X receptor (RXR) agonist drugs at /class/retinoid-x-receptor-rxr-agonist.

What development phase is Bexarotene (Targretin LGD1069) in?

Bexarotene (Targretin LGD1069) is in Phase 3.

What are the side effects of Bexarotene (Targretin LGD1069)?

Common side effects of Bexarotene (Targretin LGD1069) include Hypertriglyceridemia, Hypercholesterolemia, Headache, Asthenia/fatigue, Rash, Hypothyroidism.

What does Bexarotene (Targretin LGD1069) target?

Bexarotene (Targretin LGD1069) targets RXR (Retinoid X Receptor) and is a Retinoid X receptor (RXR) agonist.

Related